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Abstract
Obesity is a chronic disease characterized by persistent low-grade inflammation with alterations in gut motility.
Motor abnormalities suggest that obesity has effects on the enteric nervous system (ENS), which controls virtually
all gut functions. Recent studies have revealed that the gut microbiota can affect obesity and increase
inflammatory tone by modulating mucosal barrier function. Furthermore, the observation that inflammatory
conditions influence the excitability of enteric neurons may add to the gut dysfunction in obesity. In this article,
we discuss recent advances in understanding the role of gut microbiota and inflammation in the pathogenesis of
obesity and obesity-related gastrointestinal dysfunction. The potential contribution of sirtuins in protecting or
regulating the circuitry of the ENS under inflamed states is also considered.
Introduction
Obesity has dramatically increased during the past dec-
ades and has now reached epidemic proportions in both
developed and developing countries. Even in Japan where
the self-reported prevalence of obesity has remained con-
sistently low over the last 30 years, obesity is now
increasing in middle-aged adults and children [1,2] partly
due to a western-style change in diet. The increase in
obesity is associated with corresponding increases in type
2 diabetes, hypertension, cardiovascular disease and can-
cer [3]. Obesity is also associated with an increased inci-
dence of gastrointestinal (GI) disorders [4] suggesting
effects on the enteric nervous system (ENS), which con-
trols virtually all gut functions (for review see [5]).
It is generally accepted that obesity is characterized by
a low-grade chronic inflammation [6] in which pro-
inflammatory cytokines play a pivotal role. The source
of the inflammation is regarded as the adipose tissue
itself. The adipose tissue of obese individuals, including
adolescents, has been shown to produce higher levels of
tumor necrosis factor (TNF)-a and interleukin (IL)-6
compared to lean individuals [7-10]. In animal models
of diet-induced and genetic obesity increased production
of IL-1, IL-6, TNF-a and Toll-like receptor (TLR) sig-
naling in adipose tissue has also been reported [11-13].
In this review, the cause of the inflammation has been
reevaluated and the GI tract as a potential source of
inflammation and the role of gut microbiota are
explored.
A high fat (HF) diet not only modulates the release of
inflammatory mediators from adipocytes but also has a
major impact upon the gut microbiota [14], the trillions
of bacteria that normally reside within the human GI
tract and upon fermentation of non-digestible carbohy-
drates generate short-chain fatty acids [15] and promote
their absorption and storage as fat [16,17]. HF feeding
in mice induced a low-grade inflammatory tone that
was associated with changes in gut microbiota towards a
decreased number of bifidobacteria [18-20], a group of
bacteria, which has been shown to reduce lipopolysac-
charide (LPS) levels in mice and to improve mucosal
barrier function [21-23]. Interestingly, feeding obese
mice with prebiotics and changing gut microbiota in
favor of the Bifidobacterium spp. led to a significant
improvement of gut permeability that correlated with
lower portal plasma LPS levels and inflammatory tone
(i.e., decreased circulating cytokines) [18,21]. The leak-
age of gut microbiota-derived LPS into the portal blood
is a well-established mechanism of metabolic endotoxe-
mia that triggers liver inflammation and oxidative stress
[17,24]. The gut microbiota differs in composition
between lean and obese individuals [14,25]. Moreover,
alterations in gut microbiota seen in morbidly obese
subjects are modulated by weight loss due to calorie
restriction (CR) [26] or gastric bypass surgery and are
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[27,28].
This article will discuss recent advances in under-
standing the role of gut microbiota and inflammation in
the pathogenesis of obesity and obesity-related GI dys-
function. Since the silent information regulator (SIR)
genes (sirtuins) are protective against obesity-induced
inflammation and mediate, at least in part, the beneficial
effects of CR (for review see [29,30]), the potential con-
tribution of sirtuin signaling in the bowel under
inflamed states is also considered.
Gut microbiota
The human GI tract is dominated by anaerobic bacteria
belonging to three bacterial phyla: Firmicutes, Bacteroi-
detes, and Actinobacteria [31]. Greater than 90% of the
microbiota in a normal distal gut is represented by the
Bacteroidetes and Firmicutes phyla [32]. The Firmicutes,
which is the largest bacterial phylum, comprises over
200 genera of predominantly Gram-positive bacteria,
including Lactobacillus, Mycoplasma, Bacillus, and Clos-
tridium species. The Bacteroidetes phylum is composed
of three large classes of Gram-negative bacteria: Cyto-
phaga, Flavobacterium, and Bacteroidales. Members of
the Bacteroidetes and Firmicutes phyla have been shown
to be influenced by HF feeding and obesity [32-34]. The
Actinobacterium phylum consists of Gram-positive bac-
teria and includes the genus Bifidobacterium,w h i c hi s
increased upon consumption of prebiotics, indigestible
carbohydrates, which stimulate the growth of particular
species of the microflora (for review see [35]).
Initial observations to suggest that the gut microbiota
contribute to obesity were prompted by the observations
of Gordon and colleagues [16,36]. Studies in leptin-defi-
cient ob/ob mice showed a different proportion of the
two dominating divisions, Bacteroidetes and Firmicutes
compared to lean wild-type (WT) mice. Compared with
lean littermates fed the same polysaccharide-rich diet,
obesity was associated with a 50% reduction in Bacterio-
detes and a proportional division-wide increase in Firmi-
cutes in obese mice. To definitively demonstrate that
gut microbiota composition is a cause and not a conse-
quence of obesity, cecal microbiota from lean and obese
mice were transplanted into the gut of germ-free (GF)
mice. GF mice, raised from birth in sterile conditions,
are significantly thinner than microbially colonized
mice, despite eating the same amounts of food. Further-
more, after 2 weeks, conventionalization of GF mice
with the cecal microbiota from normal mice produced a
57% increase in total body fat, a 2.3-fold increase in
hepatic triglycerides, and much higher levels of leptin
production and insulin resistance which was not depen-
dent on an increase in chow consumption or changes in
energy expenditure [37,38]. Evidence was obtained to
suggest that an increased energy harvest from the diet
contributed to obesity in host GF mice. This might be
due to an increase in energy extraction due to bacterial
fermentation of polysaccharides and also to the ability
of the gut microbiota to upregulate fasting-induced adi-
pose factor, a circulating lipoprotein lipase, which
increases cellular uptake of fatty acids and triglyceride
accumulation in adipocytes. Shotgun metagenomic ana-
lysis of the gut microbiome in obese and lean mice
revealed an enrichment of genes involved in energy har-
vest in obese mice [34,38]. These included genes
involved in sensing and degrading dietary polysacchar-
ides, transporters of the resulting mono- and oligosac-
charides, and genes involved in their intracellular
metabolism. Thus, the microbiome of obese mice had
increased fermentation capabilities resulting in increased
levels of short chain fatty acids (SCFAs) in the cecum
[38]. Similarly, the gut microbiome of obese individuals
has increased fermentation capacity resulting in elevated
SCFA production [38]. Interestingly, mice deficient in
either of the SCFA receptors are leaner than their wild-
type counterparts [39], further implicating SCFAs in the
development of obesity. Currently, there is no consensus
as to whether the gut microbiota plays a causative role
in obesity or is modulated in response to the obese state
itself or the diet in obesity. Further studies, especially on
the regulatory role of SCFA in human energy homeosta-
sis are needed to clarify the physiological consequences
of an “obese style” microbiota and any putative dietary
modulation of associated disease risk.
Data from human studies were generally consistent
with the results from animal models. The first study
describing qualitative changes of the gut microbiota in
human obese subjects was published a few years ago
[40]. In this study, the analysis of fecal samples of obese
versus matched lean individuals showed a shift in bac-
terial phyla (lower Bacteroidetes and more Firmicutes).
Interestingly the authors observed that after weight loss
(following a fat restricted or a carbohydrate restricted
low calorie diet) the ratio of Bacteroidetes to Firmicutes
approached a lean type profile after 52 weeks [40]. In
addition, humans who have undergone gastric bypass
surgery for morbid obesity, have a microbial composi-
tion that is different from both obese and slim indivi-
duals [41]. A metagenomic study which included
monozygotic and dizygotic twins concordant for lean-
ness or obesity and their mothers, also showed that obe-
sity was associated with a markedly reduced bacterial
diversity, a relative depletion of Bacteroidetes, and a
higher proportion of Actinobacteria [42].
The hypothesis of more specific modulation of the gut
microbiota community in obesity (instead of those
obtained at the wide phylum levels) is supported by sev-
eral studies. Children with developmentally unusual gut
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[43] and another study found that the response of over-
weight adolescents to a diet and exercise weight-loss
program was dependent on the initial gut microbiota
prior to the treatment [26]. Moreover, differences in
fecal microbiota were shown to predict overweight in
children during the first year in life [43]. In a prospec-
tive study, Bifidobacteria spp. number was higher in
children who exhibited a normal weight at 7 years than
in children developing overweight. Moreover, they
observed that the Staphylococcus aureus were lower in
children who maintain a normal weight than in children
becoming overweight several years later. The authors
proposed that S. aureus may act as a trigger of low-
grade inflammation, contributing to the development of
obesity [43]. In agreement with these last findings, sig-
nificant differences have been observed in gut micro-
biota composition according to the body weight gain
during pregnancy [44]. They also found that the Bifido-
bacterium genus was present in higher numbers in nor-
mal-weight than in overweight women and also in
women with lower weight gain during pregnancy [44].
The Bifidobacterium genus was also poorly represented
in the fecal samples of diabetic patients compared with
healthy individuals [45].
Similar results linking gut microbiota to obesity have
been described in models of diet-induced obesity. In
mice, ingestion of a HF diet resulted in an increase of
Firmicutes and this was transmissible to lean GF recipi-
ent mice [34]. In addition, an increase in Bacteroidales
and Clostridiales was found in rats fed a HF diet regard-
less of whether they exhibit either an obesity-prone or
obesity-resistant phenotype. However, an increase in
Enterobacteriales was seen in the microbiota of obesity-
prone rats only [17]. Gut inflammation has been shown
to promote the growth of Enterobacteriaceae [46]; there-
fore, an increase in this family may be a consequence of
gut inflammation in the HF obesity prone mice rather
than a cause. Taken together, these data demonstrate
that it is the consumption of a HF diet rather than obe-
sity that accounts for the change in the gut microbiota,
but it is the development of inflammation that is asso-
ciated with the appearance of hyperphagia and an obese
phenotype.
Although humans are interested in manipulating
microbiota to aid in weight loss, the food industry has
been engaged for decades in manipulating microbiota to
increase in weight gain through the use of low-dose
antibiotics, usually called antibiotic growth promoters
(AGPs) as feed additives [47]. Evidence from the food
industry has shown that antibiotics, such as avoparcin (a
vancomycin analogue) and Firmicute probiotics (e.g.,
Lactobacillus and Enterococcus) that modify the micro-
biota can act as growth promoters increasing the size
and weight of farm animals [48]. Notably, a recent
human clinical study showed significant weight gain can
occur in humans after a six-week intravenous treatment
of vancomycin plus gentamycin for infective endocardi-
tis with a risk of obesity. Lactobacillus sp, a microorgan-
ism intrinsically resistant to vancomycin was found at
higher concentration in the feces of obese patients [49].
I nc o n t r a s t ,t h ea b s e n c eo fs p e c i f i cm i c r o b i o t ao ri t s
almost complete reduction with broad-spectrum antibio-
tics prevents or reverses HF-induced obesity [36,50].
Treatment with rifaximin (Xifaxan
®, Salix Pharmaceuti-
cals, Morrisville, NC, USA), a nonsystemic rifamycin-
derived antibiotic that exhibits low gastrointestinal
absorption while retaining potent antibacterial activity
[51] for two weeks has recently been shown to provide
significant relief of symptoms associated with IBS, such
as bloating, abdominal pain, and loose or watery stools
[52], which are also observed in obese individuals. Mod-
ulation of the gut microbiota with antibiotic therapy has
been reported in obese mice. In addition, antibiotics
reversed insulin resistance improving glycemic control
[50].
Gut inflammation and barrier function
It is now well established that obesity is an inflamma-
tory condition and that “low grade chronic” inflamma-
tion, associated with insulin and leptin resistance exists
in obese individuals [6]. The source of the inflammation
is commonly regarded as the adipose tissue itself, which
is known to produce inflammatory mediators [53]. How-
ever, the gut microbiota could also be a potential source
of inflammation.
A HF diet is associated with the expression of two
inflammatory biomarkers in the intestine, TNF-a and
nuclear factor kappa B (NF-B). The presence of gut
bacteria is required for the induction of TNF-a and NF-
B since GF mice given a similar diet did not exhibit
up-regulation of these pro-inflammatory markers [54].
Moreover, the observation that increases in intestinal
TNF-a precede yet significantly correlate with body
weight gain, body fat, and subsequent development of
insulin resistance, supports a potential role of gut-
derived TNF-a in the development of HF-induced obe-
sity and obesity-related disease [54].
Recent work has shown that gut microbiota can initi-
ate the inflammatory state of obesity through the activ-
ity of LPS, part of the outer membrane of Gram-
negative bacteria that is released into the gut lumen
when bacteria die. Cani et al. [18] reported that mice
fed a HF diet present a chronic increase in circulating
LPS, which they called “metabolic endotoxemia”.T h e
level of serum LPS is increased by about twice in obese,
diabetic, or high-fat fed individuals, by processes invol-
ving an increase in chylomicron formation, a decrease in
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tase activity, which is the enzyme responsible for the
cleavage of the LPS in the intestine [55,56,21].
LPS can trigger the inflammatory process by binding
to the CD14 toll-like receptor-4 (TLR4) complex in the
gut wall. When metabolic endotoxemia was reproduced
by subcutaneous infusion of LPS, animals developed the
same metabolic abnormalities induced by a HF diet,
while LPS knock out (CD14-/-) mice were resistant to
the effects of both HF diet and LPS infusion [57]. More-
over, chronic (4 week) administration of LPS in mice
causes hyperphagia and an increase in adiposity and
metabolic changes seen with ingestion of HF diet
[21,57]. In a subsequent experiment, changes in gut
microbiota composition induced by antibiotic treatment
reduced the cecal content of LPS and improved mea-
sures of inflammation, such as macrophage infiltration
of adipose tissue, closely correlating with an improve-
ment in the obese phenotype in both HF fed and ob/ob
mice [19].
Activation of TLR4 causes the secretion of IL-6 and
TNF-a, supporting the role of LPS in triggering the
downstream inflammatory processes associated with
obesity, such as metabolic disease [20,57]. Ingestion of a
HF diet induced a significant postprandial elevation of
LPS, accompanied by an increased mononuclear cell
expression of TLR-4, NF-ΚB and suppressor of cytokine
signaling-3 (SOCS-3), an adipokine involved in insulin
resistance [58].
Interestingly, mice genetically deficient in TLR-5 have
an altered gut microbiota composition that correlates
with obesity and several features of the metabolic syn-
drome including hyperlipidemia, hypertension, and insu-
lin resistance, which could at least in part be attributed
to increased food consumption [59]. In contrast to the
ob/ob mouse model of obesity, which is characterized by
a phylum-level shift in Bacteroidetes and Firmicutes, the
TLR5-deficient mice exhibit altered abundance in over
one-hundred specific bacterial phylotypes. A direct cau-
sal relationship between the altered gut microbiota and
obesity was demonstrated by gut microbiota transplants
where GF mice receiving the gut microbiota from TLR-
5-deficient mice gained significantly more weight com-
pared to mice that received gut microbiota from wild-
type mice [59]. These results support the emerging view
that the gut microbiota contributes to obesity and sug-
gest that malfunction of the innate immune system may
promote the development of obesity-related disorders
such as metabolic syndrome.
Mucosal barrier function is maintained by several
interrelated systems, including mucous secretion, chlor-
ide and water secretion, and binding together of epithe-
lial cells at their apical junctions by tight junction (TJ)
proteins. The disruption of the TJ complex leads to
leakage of water and proteins into the lumen, as
described in relapsing diarrhea, and to the translocation
of intraluminal solutes, such as bacterial endotoxins
(LPS), into the system circulation [60]. Activation of
TLR4 has previously been shown to alter the TJ com-
plex and increase intestinal permeability [61]. Modula-
tion of gut bacteria following a HF diet strongly
increases intestinal permeability, by reducing the expres-
sion of genes coding for two intestinal TJ proteins, ZO-
1 and occluding [19]. Alteration in occludin distribution
has also been reported in vitro on epithelial cells stimu-
lated with pro-inflammatory cytokines; thus, occludin
was chosen as a marker of TJ disruption [24,62].
Since aberrant gut microbiota and a “leaky” mucosal
barrier are found in obesity they offer potential targets
for intervention that would include modulation of the
intestinal microbiota to correct an imbalance, as well as
tightening of interepithelial junctions. Enhancement of
barrier function by probiotic bacteria has been observed
both in in vitro models and in vivo in the whole animal
[63]. Probiotics are live microorganisms that have a ben-
eficial effect on the intestinal mucosa via several pro-
posed mechanisms that include inhibition of the
mucosal adhesion of pathogens, improvement of the
barrier function of the epithelium, and alteration of the
immune activity of the host. They may also regulate
intraluminal fermentation and stabilize the intestinal
microbiota [64]. Probiotic bacteria are Lactobacilli spp.,
certain types of Streptococcus,a n dBifidobacteria spp.,
but also other non-pathogenic bacilli such as E. coli-
Nisle 1917 and yeasts such as Saccharamyces boulardii.
They secrete short chain fatty acids, an action that
results in decreased luminal pH and production of bac-
tericidal proteins. Butyric acid, a byproduct of bacterial
fermentation of fiber, has been shown to nourish colo-
nic enterocytes, enhancing mucosal integrity [65].
Researchers have demonstrated the utility of probio-
tics for obesity in HF fed mice [57,66], which is asso-
ciated with a decrease in the number of Bifidobacteria
[21]. An increase in Bifidobacteria in ob/ob mice was
associated with a significant improvement of gut perme-
ability measured in vivo; this improvement was linked to
an increase in TJ mRNA expression and protein distri-
bution [21]. In addition, the rise in Bifidobacteria was
correlated with a decrease in plasma LPS concentrations
and therefore, a significant reduction in markers of oxi-
dative and inflammatory stress [21]. Potential beneficial
effects of probiotics on gut motility via a direct action
on the ENS or epithelial cells have also been demon-
strated [67]. In experimental studies, Lactobacillus
inhibited post-infective intestinal hypercontractility
through an unidenfied, heat-labile fermentation-product
and by blocking calcium-dependent potassium channels
[68,68,69]. Supernatant of Escherichia coli Nissle 1917
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exposure of colonic mucosa to Lactobacillus rhamnosus
GG significantly reduced the acetylcholine-stimulated
human colonic contractions in a dose- and time-depen-
dent manners [70]. Administration of L. reuteri altered
the motility of ex vivo colonic segment of rat; it
decreased the amplitudes of contractions and increased
intraluminal fluid filling pressure thresholds for evoking
pressure pulses [71]. Overall, probiotics will likely have
an emerging therapeutic role in preventing and treating
obesity and obesity-related inflammation.
Gut dysfunction and obesity
Many obese individuals report symptoms suggestive of
gut dysfunction including bloating, abdominal pain and
diarrhea [4,72,73]. Bloating and upper abdominal pain
increased in frequency with increasing body mass index
(BMI). There was also a significant positive relationship
between BMI and diarrhea. In contrast, no significant
relationship was observed between BMI and constipa-
tion, even though it was more frequent in obese patients
[4]. Potential mechanisms to explain the increased bowel
frequency would be rapid gastric emptying, which has
been reported in some groups of obese patients [74],
and increased colonic motility, although the latter has
not yet been demonstrated.
Obesity is associated with gastroesophageal reflux dis-
ease (GERD), nonalcoholic fatty liver disease (NAFLD),
and increased occurrence of cholelithiasis [75,76]. GERD
has been shown to be more common in obese patients
than in those with a BMI within normal range, and an
increase in the BMI above the 95 percentile for age and
gender is a significant risk factor for GERD [77,78].
Also, a higher BMI is associated with more frequent and
more severe heartburn and regurgitation in patients
with GERD and increasing BMI is a strong predictor of
heartburn during sleep [79,80].
In patients with irritable bowel syndrome (IBS), heart-
burn was more likely to be present in subjects with obe-
sity, and epigastric pain and nausea, were also more
common in overweight patients with IBS. However, in
an adjusted log linear model, no significant interaction
was found between BMI and any other studied symptom
and heartburn was found to be independent of IBS [81].
An important and well described correlation also
exists between obesity and colorectal cancer [82]. Epide-
miologic data have shown that obesity independently
increases colorectal cancer risk, particularly in males,
but the mechanisms are poorly understood [83]. Serum
leptin level in colon cancer patients who were over-
weight or obese were significantly higher compared to
patients with normal weight [84]. mRNA levels of the
novel inflammatory factors lipocalin-2, chitinase-3 like-1
and osteopontin are increased in human visceral adipose
tissue of individuals with colon cancer [85]. Leptin upre-
gulates pro-inflammatory cytokines in discrete cells
within the mouse colon [86]. IL6, IL1b and CXCL1
were upregulated by leptin and localized to discrete cells
in gut epithelium, lamina propria, muscularis and at the
peritoneal serosal surface.
Diet-induced weight loss in obese individuals reduces
colorectal inflammation and greatly modulates inflam-
matory and cancer-related gene pathways [87]. After
weight-loss, rectosigmoid biopsies showed a 25-57%
reduction in TNF-a,I L - 1 b, and MCP-1 concentrations.
Gene arrays showed dramatic down-regulation of pro-
inflammatory cytokine and chemokine pathways, prosta-
glandin metabolism, oxidative stress pathways and the
transcription factor CREB. These data imply that obesity
is accompanied by inflammation in the colorectal
mucosa and that weight loss reduces this inflammatory
state and may thereby lower colorectal cancer risk [87].
Obesity predicts persistence of abdominal pain in chil-
dren with functional gastrointestinal disorders [88].
Obese children (mean age 13 years) were more likely to
have abdominal pain, higher intensity of pain, higher
frequency of pain, school absenteeism and disruption of
daily activities than non-obese children [88]. Obesity is
more common in children with celiac disease, a T cell-
mediated chronic autoimmune enteropathy occurring in
genetically susceptible individuals, and manifested by a
permanent intolerance of gluten-containing products
[89]. The most common presenting symptoms among
obese patients were abdominal pain, diabetes, and diar-
rhea. Symptoms improved in all patients on a gluten-
free diet.
Role of the ENS
Under both physiological and pathological conditions,
the ENS, the intrinsic innervation of the bowel, regulates
intestinal mucosal function and coordinates the activity
of the GI tract. The ENS is a component of the auto-
nomic nervous system with the unique ability to func-
tion independently from the CNS (for review, see [90]).
Enteric ganglia are organized into two major ganglio-
nated plexuses, namely the myenteric (Auerbach’s) and
submucosal (Meissner’s) plexus, and contain a variety of
functionally distinct neurons, including primary afferent
neurons, interneurons, and motor neurons, synaptically
linked to each other in microcircuits. While the myen-
teric plexus mainly regulates intestinal motility, the sub-
mucosal plexus together with nerve fibers in the lamina
propria are involved in regulating epithelial transport.
These nerves form networks within the lamina propria
of both crypts and villi with the terminal axons in close
contact with the basal lamina, an ideal position not only
to affect epithelial cell functions but also to detect
absorbed nutrients and antigens. Substances released
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change the properties of enteric neurons and cause per-
ipheral sensitization. Consequently, permanent or even
transient structural alterations in the ENS disrupt nor-
mal GI function.
The ENS is increasingly recognized as a regulatory
housekeeper of the epithelial barrier integrity, in addi-
tion to its ascribed immunomodulatory potential (for
review see [5]). Inflammation affects both epithelial
integrity and barrier function and, in turn, loss of barrier
function perpetuates the inflammatory condition. Several
studies have demonstrated structural changes within
enteric ganglia in gut inflammation (see [91,92] for
review). For example, damage to axons has been
observed in the inflamed human intestine in episodes of
inflammatory bowel disease (IBD) [93]. Other changes
that occur in the ENS during inflammation include
altered neurotransmitter synthesis, content, and release,
changes in glial and myenteric cell numbers and a
myenteric ganglionitis associated with infiltrates of lym-
phocytes, plasma cells and mast cells [94-96]. In fact,
experimental data show that gut inflammation, even if
mild, could lead to persistent changes in GI nerve and
smooth muscle function, resulting in dysmotility, hyper-
sensitivity, and dysfunction (for review see [91,92]).
Furthermore, alterations in gut function were observed
even after the resolution of an acute intestinal inflam-
mation [97-99]. Thus, the breakdown of mucosal barrier
function as occurs in obesity could cause alterations in
the patterns of gut motility, abnormal secretion, and
changes in visceral sensation that contributes to symp-
tom generation. In a rodent model of diet-induced obe-
sity the secretomotor function of submucosal neurons
was compromised, which may lead to an altered host
defense with a resultant change in intestinal flora contri-
buting to the maintenance of obesity [100]. The break-
down of mucosal barrier function may at least partially
explain the link between obesity and gut dysfunction.
Whether the persistent alterations in GI motility
observed in many obese patients are due to inflamma-
tion-related changes in the properties of enteric nerves
is not known. However, probiotic lactic acid producing-
bacteria have been shown to prevent and alleviate GI
disturbances and to normalize the cytokine profile
which might be of an advantage for patients suffering
from obesity [101].
Role of sirtuins
In the past decade, a novel class of regulators, the silent
regulator 2 (SIR2), has been linked to metabolic regula-
tion and aging and shown to mediate CR-induced long-
evity in yeast and possibly other organisms (for review
see [29]). Mammalian sirtuins are conserved with seven
genes (SIRT1-7) homologous to the yeast Sir2 gene.
Like their yeast homologs, the mammalian sirtuins are
class III histone deacetylases and require NAD(+) as a
cofactor to deacetylate substrates ranging from histones
to transcriptional regulators. The nuclear sirtuins
(SIRT1, SIRT6, and SIRT7), the mitochondrial sirtuins
(SIRT3, SIRT4, and SIRT5), and the cytosolic sirtuin
(SIRT2) regulate diverse metabolic functions. For exam-
ple, SIRT6 functions in genomic stability and transcrip-
tional control of glucose metabolism and its deficiency
(SIRT6-/-) causes a lethal hypoglycemia [102,103].
SIRT6 is highly expressed in the CNS and mice overex-
pressing SIRT6 are protected against diet-induced obe-
sity [104]. In contrast, neural-specific SIRT6 knockout
mice become obese during adult life [105], further high-
lighting the importance of SIRT6 in the context of
nutrient metabolism. SIRT3 is an integral regulator of
mitochondrial function and its depletion results in
hyperacetylation of critical mitochondrial proteins that
protect against hepatic lipotoxicity under conditions of
nutrient excess. Livers of mice fed on a HF diet had
reduced SIRT3 activity [106].
The beneficial effect of CR on aging and various meta-
bolic disorders is dependent on the activation of SIRT1
and can be mimicked by resveratrol, a product present
in grape skin and red wine, which activates the SIRT1
enzyme [107,108]. Mild to moderate red wine consump-
tion has anti-inflammatory properties, and can reduce
the risk of cardiovascular disease and cancer. The
resveratrol content in red wine is often cited to account
for this “French paradox.” Evidence for a role of sirtuins
in obesity comes from emerging understanding of the
regulatory role sirtuins play in metabolic pathways and
adaptations linked with obesity and aspects of metabolic
syndrome. These include the expression of adipocyte
cytokines (adipokines), the maturation of fat cells, insu-
lin secretion, modulation of plasma glucose levels, cho-
lesterol and lipid homeostasis and mitochondrial energy
capacity [29].
SIRT1, for example, is involved in regulating the
expression of adipokines such as adiponectin and TNF-
a, has been linked to hypothalamic control of energy
balance, plays a role in adipogenesis, and is involved in
the regulation of lipolysis and fatty acid mobilization in
response to fasting.[29] Evidence from animal studies in
which sirtuins are under- or over-expressed, and from
limited human evidence, also suggest a role for sirtuins
in obesity. Existing evidence on resveratrol suggests that
this compound may have sirtuin-mediated anti-obesity
effects [109].
Fasting leads to the up-regulation of SIRT1 in adipose
tissue of mice, pigs and humans whereas decreased
SIRT1 expression is associated with obesity [29]. In both
db/db and obese HF fed mice SIRT1 expression is low
in adipose tissue [110]. Circumstances that result in
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pogenesis, while circumstances that promote fat SIRT1
over-expression were characterized by attenuated adipo-
genesis and increased lipolysis [111]. Consistent with
this idea, lean women had more than twofold higher
SIRT1 expression compared to obese women [112].
Benefits of SIRT1 over-expression also included less
inflammation, better glucose tolerance, and almost com-
plete protection against hepatic steatosis, suggesting that
SIRT1 plays an important role in obesity-associated
metabolic adverse effects. Consequently, if activation of
SIRT1 results in loss of body fat without decreasing
caloric intake, this could open the door for novel treat-
ment and prevention strategies for obesity and related
diseases.
Genetic variation in SIRT1 is related to BMI and risk
of obesity in humans [113,114]. In a recent Belgian
case/control study of 1,068 obese patients (BMI ≥ 30
kg/m
2) and 313 normal weight control subjects, a SIRT1
single nucleotide polymorphism (SNP) associated with
visceral obesity parameters in obese men but not
women [113]. In two large and independent Dutch Cau-
casian populations, two common variants in SIRT1 were
associated with lower BMI. Carriers of these two com-
mon genetic variants had 9-11% decreased risk of being
overweight and 13-18% decreased risk of being obese
compared with noncarriers [114].
SIRT1 has recently been implicated in the regulation
of obesity-related inflammation. Zhu et al. [115] demon-
strated that resveratrol, a SIRT1 activator, decreased
TNF-a-induced MCP-1 secretion in 3T3-L1 adipocytes.
Pfluger et al. [116] showed over-expression of SIRT1 in
mice resulted in a lower level of IL-6 and TNF-a in the
serum of transgenic mice fed a HF diet and an attenu-
ated response to TNF-a-induced NF-B activation in
transgenic mouse embryonic fibroblasts. Resveratrol reg-
ulates human adipocyte number and down-regulates the
expression and secretion of IL-6 and IL-8 from mamma-
lian adipocytes in a SIRT1-dependent manner [117].
Furthermore, mice fed a diet supplemented with 0.4%
resveratrol for 10 weeks showed significantly lower body
weight and visceral fat-pad weights than HF diet fed
mice. Resveratrol significantly attenuated the HF diet-
induced up-regulation of a number of pro-inflammatory
cytokines such as TNF-a and IL-6, and their upstream
molecules, including TLR4 and NF-B in epididymal
adipose tissues of mice [12]. Thus, increased SIRT1
activity appears to be anti-inflammatory in mice and
resveratrol may improve obesity-induced inflammation
and add to the potential of this dietary polyphenol in
the control of obesity. In contrast, inhibition of SIRT1
appears to be pro-inflammatory. Studies using small
interfering RNA (siRNA) to knock down SIRT1 reported
an increase in TNF-a-induced MCP-1 and other pro-
inflammatory genes in 3T3-L1 adipocytes [118]. Taken
together, these data demonstrate that a decrease in
SIRT1 activity increases activation of NF-Ba n dt r a n -
scription of pro-inflammatory mediators. These results
have important clinical implications and may thus pro-
vide a valuable new strategy for treatment of obesity
and its related diseases.
In addition to adipose tissue, SIRT1 is highly
expressed in the hypothalamus where it appears to be
involved in regulating energy homeostasis, food intake
and body weight [108,119]. Fasting up-regulates
hypothalamic SIRT1 expression, which is associated
with a fasting-induced increase in hunger, and presum-
ably part of the complex adaptations against CR-induced
weight loss [119]. Conversely, pharmacological inhibition
of hypothalamic SIRT1 decreases food intake and body
weight gain in rodents [120], suggesting that hypothala-
mic SIRT1 decreases food intake and body weight gain
in rodents. Lack of SIRT1 in pro-opiomelanocortin
(POMC) neurons causes hypersensitivity to HF obesity
[121].
SIRT1 is also expressed in the gut where it exerts anti-
inflammatory effects in acute intestinal inflammation
and suppresses intestinal tumorigenesis and colon can-
cer associated with colitis [122-124]. Rats fed with 1 mg
of resveratrol/kg/day (a human equivalent dose) for 25
days, and in the last five days, 5% DSS to induce colitis,
displayed increased lactobacilli and bifidobacteria as well
as a reduced increase in enterobacteria upon DSS treat-
ment. In addition, resveratrol significantly protected the
colonic mucosa architecture, reduced body weight loss,
diminished the induced anemia and reduced systemic
inflammatory markers possibly via the down-regulation
of NF-B [124]. Also, resveratrol up-regulated SIRT1
expression in the mucosa and mitigated the increase in
the number of mucosal CD4+ T cells suggesting that
resveratrol may exert its anti-inflammatory effects by
modulating activated immune cells [123]. Thus, activa-
tion of SIRT1 maintains gut barrier function, which is
compromised in obesity [125] and through its regulation
of gut inflammation controls colitis and colon cancer,
which are also more prevalent in obese individuals
[126].
The ENS also contains sirtuins. We have shown for
the first time that neurons in the murine colon display
SIRT1 immunoreactivity (Figure 1). The cellular locali-
zation of SIRT1 is predominantly nuclear and displayed
by neurons in both the submucosal and myenteric
plexus consistent with areas strongly compromised by
aging [127]. These findings propose a role for SIRT1 in
gut motility and secretion and suggest a previously
unrecognized role of enteric SIRT1 in regulating energy
homeostasis. Moreover, activation of enteric sirtuin
pathways could offer a therapeutic approach to treat
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is required to explore the role of sirtuin proteins in
enteric neurobiology during normal and inflamed states.
Conclusions
Obesity is considered a major public health concern
globally as it predisposes to a number of chronic human
diseases. Recent studies report an aberrant gut micro-
biota in obese individuals and that gut microbial meta-
bolic activities, especially fermentation can impact on a
number of mammalian physiological functions linked to
obesity. Those data suggest that specific changes in the
gut microbiota characterize the obese state and asso-
ciated metabolic diseases, including diabetes. Gut micro-
biota, which affect barrier function also modulate the
activity of the ENS, a key player in gut dysfunction.
Since aberrant gut microbiota and a “leaky” mucosal
barrier are found in obesity they offer potential targets
for intervention that would include modulation of the
intestinal microbiota to correct an imbalance, as well as
tightening of interepithelial junctions. However, we may
not conclude, from the papers published until now, that
targeting one specific bacterial target is sufficient to get
an improvement of a complex disease such as obesity.
Future studies using newly developed techniques to
evaluate the gut microbiota in obese patients and/or ani-
mal models of obesity are certainly needed. In addition,
future research should focus on the role of sirtuin pro-
teins in the gut and their function in obesity and gut
dysfunction. Studies suggest that resveratrol acts as an
anti-inflammatory agent in the gut by targeting the
SIRT1 gene. Thus, resveratrol may be a therapeutic tar-
get against obesity-related inflammation and gut
dysfunction.
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Figure 1 Immunohistochemical localization of the class III histone deacetylase SIRT1 (Sir2) in the murine enteric nervous system. A.
Confocal image of a whole mount preparation of colon stained with a goat antibody to the neuronal marker human neuronal protein (HuD;
1:100; Santa Cruz; sc-5977; green). HuD immunoreactivity is displayed by neurons in a myenteric ganglion. B. Double label confocal image of the
same area depicted in A stained with an antibody to HuD and a SIRT1-specific antibody made in rabbit (1:500; Abcam Inc. Cambridge MA; ab
16640). Myenteric neurons display both HuD (green) and nuclear SIRT1 immunoreactivity (red). For whole-mount preparations, segments of
colon were cut along the mesenteric border and the resulting sheet of gut was pinned flat, mucosal side up, in a silicone elastomer (Sylgard,
Dow Corning, Midland, MI)-coated dish. The tissue was fixed for 3 hours with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). After
fixation, the preparations were washed in phosphate-buffered saline (PBS) for 1 hour and whole-mount preparations of longitudinal muscle with
adherent myenteric plexus (LMMP) were generated as previously described [128]. Non-specific binding was blocked by incubating the
preparations with 6% (v/v) normal horse serum, with Triton X-100 (0.5%), in PBS for 60 minutes. The preparations were then exposed for 24 h to
primary antibodies at 4°C. After washing with PBS, sites of bound primary antibodies were detected by incubation with donkey anti-rabbit or
donkey anti-goat secondary antibodies coupled to DyLight™ 549 (1:400; Jackson ImmunoResearch Labs.West Grove, PA) or DyLight™ 488
(1:400; Jackson ImmunoResearch Labs.) for 3 hours. Confocal images were obtained using an Olympus FluoView FV300 confocal microscope.
Scale bar, 30 μm.
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